Press Release

Pharnext to Host Research and Development Event Today

Event to be held virtually as a live webcast today starting at 8:00 a.m. ET/ 2:00 p.m. CET

PARIS, France, 08:30 a.m. CET, October 13, 2020 – Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, will be hosting a research and development (R&D) event today, as a live webcast, focused on the company's development efforts related to its lead asset, PXT3003, in Charcot-Marie-Tooth disease type 1A (CMT1A) from 8:00 to 10:30 a.m. ET / 2:00 to 4:30 p.m. CET.

The agenda will include:

CMT1A disease overview
***Mario Saporta, M.D., Ph.D., MBA, FAAN**, Associate Professor of Neurology & Human Genetics, Miller School of Medicine, University of Miami; Director of the Charcot-Marie-Tooth Center of Excellence at the MDA care center, University of Miami*

CMT1A patient perspective
***Allison Moore**, Founder and Chief Executive Officer, Hereditary Neuropathy Foundation*

PXT3003 Program Overview
***Adrian Hepner, M.D., Ph.D.**, Chief Medical Officer and Head of R&D, Pharnext*

Pleotherapy™ AI Platform Overview
***David Horn Solomon**, Chief Executive Officer, Pharnext*

The event will conclude with a panel discussion involving the keynote speakers together with Pharnext senior management and will provide an opportunity for Q&A.

Virtual Event Details

The event will be webcast live today, October 13th starting at 8:00 a.m. ET / 2:00 p.m. CET and may be accessed by visiting the "Investors" section of the Pharnext website (www.pharnext.com) or by following this link: https://bit.ly/3d6l038. An archived webcast will also be available on Pharnext's website following the event.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase II results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

Contacts

David Horn Solomon
Chief Executive Officer
contact@pharnext.com
+33 (0)1 41 09 22 30

Media Relations (International)
Consilium Strategic Communications
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
pharnext@consilium-comms.com

Media Relations (U.S.)
Rooney Partners LLC
Jeffrey Freedman
jfreedman@rooneyco.com
+1 646 432 0191

Media Relations (France)
Ulysse Communication
Bruno Arabian
+33 (0)6 87 88 47 26
barabian@ulysse-communication.com
Pierre-Louis Germain
+33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
+33 (0)1 81 70 96 30

Investors Relations (U.S.)
Stern Investor Relations, Inc.
Janhavi Mohite
janhavi.mohite@sternir.com
+1 212 362 1200

Financial Communication (Europe)
Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15